BREAST CANCER BASE

What is the endocrine treatment, which is preferable to patients with breast cancer endocrine therapy The breast itself is an endocrine organ, the incidence of breast cancer and the body endocrine dysfunction. The endocrine therapy in breast ...

Application of breast cancer after Femara for endocrine therapy? No chemotherapy directly with Femara work? The world at present, after receptor-positive breast cancer patients using complementary therapy...

For ER / PR positive only bone / tissue transfer or asymptomatic visceral metastasis in patients with breast cancer, dealing with the following principles : (a) For the year received anti-estrogen treatment of patients with the option of aromatase inhibitors or progesterone hormones or other endocrine drug therapy, straight tumor progression to occur or tolerance of toxicity. If the tumor further progress, and accept a three rescue endocrine treatment programs, not clinical benefit or any of the symptoms associated with visceral metastasis, one can consider switching to systemic chemotherapy, on the other hand may also consider accepting new endocrine therapy clinical trials. (2) not previously received anti-estrogen therapy, or anti-estrogen therapy has been more than a year of patients. If for postmenopausal patients, it may consider preferred or anti-estrogen drug therapy; If not menopausal patients should first conduct ovariectomized or inhibit ovarian function and click postmenopausal principles, preferred choice or anti-estrogen therapy. If the tumor further progress, and accept a three rescue endocrine treatment programs, not clinical benefit or any of the symptoms associated with visceral metastasis, one can consider switching to systemic chemotherapy, on the other hand may also consider accepting new endocrine therapy clinical trials. But special emphasis on the need for the past received anti-estrogen treatment, which has more than a year of patients, although in 2006 NCCN treatment guidelines that can use anti-estrogen therapy. But Furlong P025 tests show that used auxiliary TAM, to stop more than a year of failure patients, and then only TAM efficiency 8%. Therefore we believe that this group of patients should be possible to evade the TAM option to switch to anastrozole.

For ER / PR-negative or accompanied by symptoms of visceral metastasis or endocrine therapy for patients with tolerance, if HER-2 overexpression against HER-2 antibody Herceptin alone or combined with chemotherapy is the recommended treatment options; For HER-2-negative patients, chemotherapy for the preferred. If either of those two patients in three treatment programs ineffective, or ECOG physical situation score ≥ 3 and no longer consider further options cytotoxic chemotherapy treatment.

Breast cancer endocrine therapy is not appropriate for everyone For the treatment of breast cancer, in addition to traditional surgery and radiotherapy and chemotherapy, in recent years the medical profe...

Breast cancer is a phased matter how Breast cancer is a phased matter how The staging of breast cancer patients is under the lesion size, lymph node metastasis and distant met...

Hormonal therapy for breast cancer In the treatment of breast cancer, in addition to surgery, radiation, anti-cancer drugs and herbs, there is a hormonal therapy, according t...

Male breast cancer resection of the testis Male breast cancer in clinical relatively rare, most of the total breast cancer only about 1%. Male breast cancer incidence average age than...

Hormonal therapy for breast cancer merits We need to first understand the endocrine therapy is a clear mechanism, blocking estrogen on tumor growth stimulating effect on normal cells...

Breast cancer endocrine treatment which? Breast cancer and endocrine (particularly ovarian) is close to endocrine therapy in the disease only palliative effect, but in the conserva...

Recurrent breast cancer treatment

New drugs can reduce breast cancer recurrence rate